ARCUTIS BIOTHERAPEUTIC

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

29 7 2024 07:35:00 提供 Nasdaq GlobeNewswire

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

29 7 2024 07:30:00 提供 Nasdaq GlobeNewswire

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

23 7 2024 08:00:01 提供 Nasdaq GlobeNewswire

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

22 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

09 7 2024 16:53:01 提供 Nasdaq GlobeNewswire

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

09 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 7 2024 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

10 6 2024 14:30:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 6 2024 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

03 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

14 5 2024 16:00:00 提供 Nasdaq GlobeNewswire

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

13 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 5 2024 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

29 4 2024 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Appoints David Topper as Chief Financial Officer

10 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 4 2024 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

28 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

11 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

10 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

09 3 2024 16:00:00 提供 Nasdaq GlobeNewswire